Dihydroartemisinin remodels macrophage into an M1 phenotype via ferroptosis-mediated DNA damage

Liu-Gen Li1,2,3†, Xing-Chun Peng2,3,4,†, Ting-Ting Yu1,2,3, Hua-Zhen Xu5, Ning Han1,2,3, Xiao-Xin Yang6, Qi-Rui Li2,3, Jun Hu1,2,3, Bin Liu2,3, Zi-Yi Yang2,3, Xiang Xu2,3, Xiao Chen5, Mei-Fang Wang1,3* and Tong-Fei Li1,2,3,4*

1Department of Respiratory, Taihe Hospital of Shiyan, Hubei University of Medicine, Shiyan, China, 2School of Basic Medical Sciences, Hubei University of Medicine, Shiyan, China, 3Hubei Key Laboratory of Embryonic Stem Cell Research, Hubei University of Medicine, Shiyan, China, 4Department of Pathology, Sinopharm DongFeng General Hospital, Hubei University of Medicine, Shiyan, China, 5Department of Pharmacology, School of Basic Medical Sciences, Wuhan University, Wuhan, China, 6School Institute of Chemical Biology and Nanomedicine, State Key Laboratory of Chemo/Biosensing and Chemometrics, College of Chemistry and Chemical Engineering, Hunan University, Changsha, China

Lung cancer recruits tumor-associated macrophages (TAMs) massively, whose predominantly pro-tumor M2 phenotype leads to immunosuppression. Dihydroartemisinin (DHA) has been proven to remodel TAM into an anti-tumor M1 phenotype at certain concentrations in the present study, which was hypothesized to facilitate anti-lung cancer immunotherapy. However, how DHA remodels the TAM phenotype has not yet been uncovered. Our previous work revealed that DHA could trigger ferroptosis in lung cancer cells, which may also be observed in TAM thereupon. Sequentially, in the current study, DHA was found to remodel TAM into the M1 phenotype in vitro and in vivo. Simultaneously, DHA was observed to trigger ferroptosis in TAM and cause the DNA damage response and NF-κB activation. Conversely, the DHA-induced DNA damage response and NF-κB activation in TAM were attenuated after the inhibition of ferroptosis in TAM using an inhibitor of ferroptosis. Importantly, a ferroptosis inhibitor could also abolish the DHA-induced phenotypic remodeling of TAM toward the M1 phenotype. In a nutshell, this work demonstrates that DHA-triggered ferroptosis of TAM results in DNA damage, which could activate downstream NF-κB to remodel TAM into an M1 phenotype, providing a novel strategy for anti-lung cancer immunotherapy. This study offers a novel strategy and theoretical basis for the use of traditional Chinese medicine monomers to regulate the anti-tumor immune response, as well as a new therapeutic target for TAM phenotype remodeling.

KEYWORDS
tumor-associated macrophages (TAMs), dihydroartemisinin (DHA), ferroptosis, DNA damage, NF-κB
Introduction

Lung cancer, especially non-small-cell lung cancer (NSCLC), occupies the top three positions in the incidence of malignancies and is the leading cause of mortality in urban cases of cancer (Duma et al., 2019; Yang et al., 2020; Siegel et al., 2022). NSCLC’s microenvironment is characterized by the presence of a large number of tumor-associated macrophages (TAMs), which display an immunosuppressive M2 phenotype (Li et al., 2018; Hwang et al., 2020). TAM interacts with lung cancer cells and various types of immunocytes (Singhal et al., 2019; Wei et al., 2019), promoting the proliferation of malignant cells and repressing the anti-tumor immune response (Lavin et al., 2017). This has resulted in lung cancer being difficult to be completely destroyed and highly susceptible to recurrence and metastasis. However, the phenotype of TAM can be reprogrammed to an immune-excitatory, anti-tumor M1 phenotype under certain conditions (Li et al., 2017; Parayath et al., 2018; Osipov et al., 2019; Lu et al., 2020; Sarode et al., 2020; Xu et al., 2021; Yu et al., 2021). Therefore, remodeling the phenotype of TAM has become a crucial strategy of great interest in immunotherapy of lung cancer.

Dihydroartemisinin (DHA) is a multipotent chemotherapeutic agent (Keating, 2012; Tu, 2016; Dai et al., 2021). In addition to its ability to destroy plasmodium, DHA has been investigated for its cytotoxic effects on malignant cells of various solid tumors, including esophageal cancer, breast cancer, and glioma (Kumar et al., 2019; Liu et al., 2019; Wan et al., 2019). However, few studies are concerned with the effect of DHA on immunocytes. It is reported that DHA can induce ferroptosis by down-regulating glutathione (GSH) and glutathione peroxidase 4 (GPX4), and promoting the intracellular accumulation of reactive oxygen species (ROS) and lipid peroxide (LPO) (Chen et al., 2020; Yi et al., 2020). Our previous work also revealed that DHA uptake by lung cancer cells effectively induced apoptosis. More importantly, the transferrin-1 (TfR1) and cyclooxygenase-2 (COX-2) expression were up-regulated along with an intracellular accumulation of LPO, but the GPX4 expression was decreased (Han et al., 2022). Based on the aforementioned, DHA is likewise able to trigger the occurrence of ferroptosis in TAM. DHA generates certain concentrations of ROS and LPO in TAM by triggering ferroptosis, which results in oxidative damage to the DNA of TAM. Supposedly, interferon-stimulating molecules (STING) in the cytoplasm have been identified to be activated by fragments of damaged DNA, which in turn revitalizes its downstream NF-κB signaling pathway (Hou et al., 2018; Yum et al., 2021). This inflammatory signaling, on the other hand, can polarize macrophages into a pro-inflammatory, anti-tumor M1 phenotype (Lin et al., 2020; Yu et al., 2022).

DHA showed a significant remodeling effect on mouse primary macrophages toward the M1 phenotype. Similarly, macrophage infiltration and phenotypic remodeling were enhanced in the tumor tissues of DHA-treated lung cancer cell-bearing mice. Further studies indicated that DHA treatment also initiated ferroptosis, DNA damage, and NF-κB activation in TAM. But the inhibition of ferroptosis in TAM significantly attenuated the DHA-induced DNA damage and NF-κB activation. Synchronously, the inhibition of ferroptosis also weakened the phenotypic remodeling of TAM by DHA. The current study for the first time uncovered the mechanism by which DHA reprograms macrophages through ferroptosis, providing a novel approach for the intervention in TAM phenotypic remodeling.
Material and methods

Cell models and DHA treatment

According to a previous study (Xu et al., 2021), mouse bone marrow-derived cells were extracted from C57/BL mice at 4–5 weeks of age (Laboratory Animal Center at the Hubei University of Medicine, Hubei, China). Macrophage colony-stimulating factor (M-CSF) was applied to induce mouse bone marrow-derived cells into mouse bone marrow-derived macrophages (mBMDMs). Upon this foundation, IL-4 and IL-13 were added to the mBMDM for 2 days to promote its polarization to M2, yielding the mouse TAM (Supplementary Figure S1). Alternatively, Lewis cells were utilized as a model for mouse lung cancer cells. Lewis cells were purchased from the Cell Bank of Shanghai Institutes for Biological Sciences (Shanghai, China). All cells were cultured in DMEM (Sigma-Aldrich, St Louis, United States) supplemented with 10% fetal bovine serum (QmSuero/Tsingmu Biotechnology, Wuhan) in an incubator (5% CO₂/95% air ambience, 37°C). DHA (77,939-50-9, MERYER, Shanghai, China, 98% purity) was applied to treat TAM for about 18 h. The concentration of DHA used in this work ranged from 5 μg/ml to 60 μg/ml.

TAM viability detection

In order to evaluate the efficacy, TAMs were treated with DHA for 18 h. TAMs were plated in 96-well plates with a density of 6 × 10⁴ per well treated with DHA (different concentrations) for 18 h. The cell viability was detected using a CCK-8 Kit (HY-K0301, MCE, NJ, United States).

Phenotype assay of macrophages

DHA-treated TAMs were harvested, and then marked with fluorescein-linked CD206 and CD86. The surface expression of CD206 and CD86 was detected by flow cytometry. In addition, MHC-II expression was assayed through immunofluorescence staining and observed with microscopy. Alternatively, proteins of TAM were harvested. The expression of iNOS and GBP5 was assayed by Western blotting (WB). Furthermore, phagocytosis function was analyzed by the incubation of latex beads. The activated latex beads were incubated with DHA-treated TAMs for 2 h. Cells were washed with PBS three times and fixed using 4% paraformaldehyde, and then labeled with Hoechst 33,342. The latex beads in mBMDM were detected using laser scanning confocal microscopy (LSCM). Moreover, IL-6 and IL-1β expression of mRNA were detected by a real-time PCR (RT-PCR). Finally, the release of IL-6 and IL-1β was measured with Elisa kits (CME0006/CME0015, purchased from 4A Biotech Co., Ltd.).

ROS detection

TAMs were seeded in 24-well plates with a density of 3×10⁵ cells per well, and then incubated with DHA for 18 h. The cells were then washed with PBS three times and incubated with 10 μM of 2,7-dichlorodi-hydrofluorescein diacetate (DCFH-DA, S0033, Beyotime, Shanghai, China) at 37°C for 40 min before being harvested and assayed by flow cytometry.

Observation of ferroptosis

For the assay of TAM’s ferroptosis, first intracellular Fe ions were investigated. In brief, the PGSK probe was applied to label TAM for 15 min. After that, the fluorescent dye was removed. The cells were washed with PBS three times. The FITC fluorescence of PGSK-labelled TAM was analyzed through flow cytometry. Since the PGSK probe can be quenched by iron ions, lower intracellular fluorescence indicates a higher iron ion concentration. Moreover, malondialdehyde (MDA) production, which is an indicator of ferroptosis, in TAM was detected using an MDA Assay Kit (E-BC-K025-S, Elabscience).

DAN damage detection

DNA double-strand breaks (DDSBs) were detected by the comet assay (Olive and Banáth, 2006). In brief, TAMs were seeded in 24-well plates and treated with DHA. Cells in PBS were prepared and mixed with a low melting point agarose. The mixture was then dripped onto a glass slide pre-coated with agarose gel and pressed, followed by electrophoresis at 20 V, 250 mA for 20 min. The mixture was then neutralized using tris-Hcl (PH = 6.0) for 30 min. Finally, Hoechst 33,342 was used to stain the nuclei. The cells were photoed using fluorescence microscope. For DNA damage response analysis, TAM in the 6-well plates were treated with DHA. Then total proteins were extracted for WB assay of γ-H2A.X and p53 expression.

Assay of activation of NF-κB

TAMs were seeded in 6-well plates or special dishes, and treated as mentioned previously. First, the expression of NF-κB, p-NF-κB was detected by WB. Alternatively, the nuclear translocation of NF-κB was analyzed through immunofluorescent staining of NF-κB and LSCM.

Inhibition of ferroptosis

For the inhibition of TAM’s ferroptosis, ferrostatin-1 (Fer-1, 2 μM) was applied to treat TAM along with DHA for 16–20 h.
The ferroptosis of TAM was evaluated following the blockage to confirm the successful blockage.

Measurement of anti-tumor efficacy

To examine the anti-tumor efficacy of DHA-treated TAM, Lewis lung cancer cells (LLC) were co-cultured with TAM with or without DHA treatment for another 24 h. The LLC could be harvested based on the different attachment capacities. The obtained cells were stained with Annexin-V/PI (purchased from CHAMOT BIOTECHNOLOGY CO., LTD.), and then analyzed by flow cytometry. Alternatively, the cell viability of LLC was detected using the CCK-8 Kit as described previously. At the same time, proteins of LLC were extracted to analyze the expression of apoptosis-associated molecules.

Immuno-fluorescent staining of CD86, CD206, NF-κB, and MHC-II

For the detection of surface expression of MHC-II or the location of NF-κB, cells were incubated with primary antibodies of CD86 (212927, Elabscience, China), CD206 (B354282, Biolegend, United States), NF-κB (10745-1-AP, Proteintech, Wuhan, China), and MHC-II (sc-66205, SANTA CRUZ BIOTECHNOLOGY, Santa Cruz, America) overnight at 4°C, and then incubated with goat anti-rat IgG/Alexa fluor 488 secondary antibodies (bs-0293G-AF488, Bioss, Beijing, China) for another 120 min. After incubating with fluorescent secondary antibodies, the cells were washed three times before flow cytometry or LSCM.

Flow cytometry detection

Fluorescence of FITC-Annexin-V, DCFH-DA, C11-BODIPY-FITC, and Alexa fluor 488 was acquired in the FITC channel. PI and C11-BODIPY-PE fluorescence was acquired in the PE channel. The excitation wavelength and emission wavelength were 488 nm and 525 nm in the FITC channel, 561 nm and 585 nm in the PE channel, respectively. After cells were processed and collected as described previously, they were filtered into special tubes for flow cytometry. Each channel was adjusted to the appropriate voltage before collecting cells. At least 1 × 10⁴ cells per sample were acquired for every collection. Geometric means (GM) were used to quantify the mean fluorescent intensity (MFI).

Western blotting

TAM treated by DHA or other controls were washed three times with PBS and lysed in a RIPA buffer with 1% protease inhibitor for 40 min. Cell lysates were centrifuged and protein concentration was measured using a BCA Assay Kit. Equal proteins (10–30 μg) were fractionated by SDS-PAGE and transferred to a PVDF membrane. The membranes were blocked with 3–5% bovine serum albumin in TBST and incubated with primary antibodies of iNOS (ab15323, Abcam, Cambridge, United Kingdom), GBP5 (13220-1-AP, Proteintech, Wuhan, China), p53 (bs-2090R, Bioss, Beijing, China), γ-H2AX (bs-3185R, Bioss, Beijing, China), NF-κB (10745-1-AP, Proteintech, Wuhan, China), p-NF-κB (bs-0982R, Bioss, Beijing, China), and GAPDH (PMK053C, BioPM, Wuhan, China) overnight at 4°C. Then the membranes were incubated with horseradish peroxidase-conjugated secondary antibodies. Protein bands were reacted using an ECL kit (PMK003, BioPM, Wuhan, China), and the films were exposed using a Bio-Imaging system (170-8265, Bio-Rad).

RT-PCR assay

mRNA of TAM was extracted and reverse-transcribed to cDNA, which was amplified using an SYBR Green qPCR Master Mix kit (PC3301, Beijing, Aidlab). RT-PCR was performed using a Bio-RAD CFX Connect Optics Module and data were analyzed using Bio-RAD CFX Manager. The specific primer sequences are as follows:

Mouse interleukin-1β (IL-1β) forward: AGCTCCCTTTTTGTTGAATGAGCAGA
Mouse IL-1β reverse: ATGGTTTCTTTGTGACCCTGAGCGAC
Mouse IL-12b forward: ATGAAGGAGACAGAGGGGGTGTA
Mouse IL-12b reverse: TGCTGCATGAGAGAATTGTAATAGCGA
Mouse cyclooxygenase-2 (COX-2) forward: TGAGTACCGCAAACGCTTCT
Mouse COX-2 reverse: CTCCCCAAAGATAGCATCTGG
Mouse IL-6 forward: CCGAGAGGAGACTTCACAGAG
Mouse IL-6 reverse: ATTTCCACGATTTCCCAGAG
Mouse glutathione peroxidase 4 (GPX4) forward: TTCAGCTCTGAGGAAATGGTAATAGCGA
Mouse GPX4 reverse: CCTCCCATGAGCAGCTTACTCCAGAG
Mouse transferrin-1 (TfR1) forward: CTGGCTCTCACA
Mouse TfR1 reverse: GCATTTGCGACTCCCTGAATA GTCC
Mouse IL-10 forward: AGCTCCAGAGACCAAGGTGTCTACAAG
Mouse IL-10 reverse: AGTCCAGAGACCTAATCACACTG
Mouse transforming growth factor-β (TGF-β) forward: CCTGCCCTTATTTTGAGCCTGGA
Immunohistochemistry assay in lung cancer cell-bearing mice

Female C57BL/6 mice at 5–6 weeks of age (18–20 g) were housed in the Animal Center at the Hubei University of Medicine (Hubei, China) with a temperature-controlled environment, fresh water, and rodent diet. Animal handling and experimental procedures were in line with protocols approved by the Animal Care Committee at the Hubei University of Medicine. All inoculations and treatments were carried out under Nembutal anesthesia. To investigate the effects of DHA on the ferroptosis, DNA damage, NF-κB activation, and phenotype of TAM, LLC-bearing mice received DHA treatment. For about 24 h after treatment, the mice were sacrificed. The tumor grafts were harvested. Fresh tissues of neoplasm were crushed and assayed for their internal iron
ions. Paraffin sections of neoplastic tissue were dewaxed, rehydrated, and antigen-repaired with sodium citrate for 15 min. Then the paraffin sections were subjected to incubation in 3% hydrogen peroxide at room temperature for 15 min. Paraffin sections were blocked with 5% BSA for 60 min, dyed with primary antibodies overnight at 4°C, and then stained with secondary antibody (PV-9000, ZSGB-BIO, Beijing, China) for 1 h at 37°C. Diaminobenzidine (DAB, ZL-9018, ZSGB-BIO, Beijing, China) was used for staining at room temperature for 1–3 min. The nuclei were stained with hematoxylin or DAPI.

**FIGURE 2**
DHA reprogrammed macrophages into the M1 phenotype in tumor tissues. **(A)** The expression of CD11b, which is a biomarker of macrophages, was assayed by IHC. In addition, M1 phenotypic molecules, such as iNOS, MHC-II, and GBP5, were detected through IHC as well. **(B,C)** F4/80/iNOS and F4/80/GBP5 double-positive cells in the tumor grafts were counted. **(D,E)** The infiltration and phenotypic remodeling of macrophages were assayed by multiple immunofluorescent staining of F4/80 and iNOS, GBP5. Green fluorescence came from F4/80. Red fluorescence came from iNOS or GBP5. Yellow fluorescence represented F4/80/iNOS or F4/80/GBP5 double-positive cells (type-I macrophages). Values were means ± SD (n = 3, *p < 0.05 when compared with the control group).
Primary antibodies included CD11b (66519-1-Ig, Proteintech, Wuhan, China), F4/80 (E00611-1637, eBioscience, United States), iNOS (ab15323, Abcam, Cambridge, United Kingdom), GBP5 (13220-1-AP, Proteintech, Wuhan, China), MHC-II (sc-66205, SANTA CRUZ BIOTECHNOLOGY, Santa Cruz, United States), GPX4 (14432-1-AP, Proteintech, Wuhan, China), COX-2 (A1253, Abclonal, Wuhan, China), γ-H2A.X (bs-3185R, Bioss, Beijing, China), MDA (sc-66205, SANTA CRUZ BIOTECHNOLOGY, Santa Cruz, United States), COX-2 (A1253, Abclonal, Wuhan, China), γ-H2A.X (bs-3185R, Bioss, Beijing, China).
DHA showed outstanding ability for phenotypic remodeling of macrophages toward M1

Before exploring DHA’s effect on the phenotypic remodeling of TAM, the viability of macrophages was investigated first. The viability of TAM varied little in the presence of DHA as presented in Supplementary Figure S2. Subsequently, as shown in Figure 1, the phenotype of the macrophage was assayed. The biomarkers of the M1 phenotype, surface CD86, were up-regulated synchronously (Figures 1A,B). In addition, the expression of IL-1β, IL-6, and IL-12b, which are crucial pro-inflammatory cytokines, increased in DHA-treated TAM (Figures 1C–E). In agreement with the mRNA expression, the release of IL-1β and IL-6 was also elevated in the presence of DHA (Figures 1F,G). Moreover, the results of iNOS and GBP5 expression showed significant regulation in macrophages treated by DHA (Figures 1H–J). Furthermore, the obvious M1 phenotype transformation of DHA-treated macrophages was indicated by the enhanced functions of antigen presentation and phagocytosis, characterized by the enhanced expression of MHC-II and endocytic latex beats of TAM (Figures 1K,L). Interestingly but not surprisingly, the indicators of M2 phenotype such as CD206, IL-10, and TGF-β were down-regulated in response to DHA, suggesting depolarization of TAM (Supplementary Figure S3). Consistent with the in vitro findings, there was obvious macrophage infiltration in the tumor grafts of mice that received DHA treatment, as suggested by the significant CD11b expression. Importantly, the tumor tissue of mice treated with DHA showed enhanced iNOS, GBP5, and MHC-II expression, indicating the M1 reprogramming of TAM inside the tumor tissue (Figure 2A). In addition, more F4/80/iNOS or F4/80/GBP5 double-positive cells could be observed in the tumor grafts of mice treated by DHA (Figures 2B–E). The findings of co-staining of F4/80, GBP5, and iNOS were crucial evidence that DHA remodels TAM into an M1 phenotype in tumor tissues. In a word, TAM treated with DHA exhibited apparent M1 phenotype reprogramming.
DHA induced ferroptosis of macrophage

Elucidating how DHA regulates TAM for the M1 phenotype is of critical interest for understanding the pharmacological effects of DHA. With this concern in mind, we first explored what happened upstream after the action of DHA on TAM. As mentioned previously, given that DHA can induce ferroptosis in lung cancer cells, did the action on TAM trigger the ferroptosis as well? As expected, the iron ions in TAM were significantly lower than those in lung cancer cells. However, DHA treatment promoted the accumulation of iron ions (Figures 3A,B), which may be associated with the up-regulation of TfR1 (Figure 3C). The PGSK probe is a common reagent for the detection of cellular iron ions, whose fluorescence can be quenched by iron ions in living cells. Thus, low fluorescence implied a higher concentration of iron ions in TAM. As reported, TIR1 contributes to the influx of iron ions in most cells. In addition to increased iron ions, the represented molecule of the reducing system GPX4 in TAM was down-regulated in the presence of DHA (Figure 3D). We then investigated the cellular ROS and LPO generation. As shown in Figure 3 e-f and i-k, after incubation with DHA, increased DCFH-DA fluorescence and FITC-C11-BODIPY positive cells in TAM were observed, indicating the accumulation of ROS and LPO. In addition, the expression of COX-2 and MDA accumulation, biomarkers of ferroptosis, up-regulated in response to DHA as well (Figures 3G,H). Notably, the ROS generation and up-regulation of TIR1 were more significantly at 30 μg/ml than 60 μg/ml, which may be associated with the decreased viability of TAM. The in vivo results also displayed stronger ferroptosis in lung cancer cell-bearing mice that received DHA treatment, as indicated by the augmented expression of COX-2 and reduced expression of GPX4 (Figure 4A). Furthermore, in agreement with the in vitro...
data, the iron ions were elevated in mice treated with DHA (Figures 4B,C). These findings strongly suggest that DHA promoted iron ion enrichment and inhibited GPX4, thereby generating ROS and LPO, resulting in the induction of ferroptosis in macrophages.

**DHA-treated TAM exhibited enhanced DNA damage and activation of NF-κB**

The generated ROS and LPO accompanied with the ferroptosis of TAM possess the function of attacking DNA, causing DNA damage such as DNA double-strand break (DDSB). Therefore, the DNA fragments and subsequent DNA damage response (DDR) in TAM treated with DHA were investigated. The visible but not very serious DDSB could be monitored in the DHA treated group with the comet assay (Figures 5A,B). Along with that, the DDR in TAM treated with DHA was observed, as indicated by the enhanced expression of γ-H2A.X and p53 (Figures 5C–E). Furthermore, DHA-treated TAM showed significant activation of NF-κB, which was characterized by phosphorylation and nuclear-translocation of NF-κB (Figures 5F–I). The in vivo results were in agreement with the in vitro findings. As presented in Figure 6, the DNA damage and activation of NF-κB were demonstrated in the tumor grafts of DHA-treated mice, as evidenced by the enhanced expression of γ-H2A.X, p53, and NF-κB detected by IHC. Since NF-κB is a downstream signal of DNA damage, it could lead to the inflammatory reaction of TAM. There is speculation that this may be related to the M1 phenotypic remodeling of macrophages. Taken together, TAM treated with DHA exhibited prominent DNA damage and NF-κB activation. Based on this proof, we speculated that DHA-mediated ferroptosis in TAM produced adequate ROS and LPO, resulting in DNA damage and subsequent DDR to activate the NF-κB molecule. TAM were polarized into pro-inflammatory phenotype (M1) by the activated NF-κB signaling pathway thereupon.

**Blockage of ferroptosis impaired DHA-mediated DNA damage and reprogramming in macrophages**

In order to establish the logical link among DHA-induced ferroptosis, DNA damage, and phenotypic remodeling in TAM, ferrostatin-1 (Fer-1), the LPO scavenger, was applied to inhibit the TAM’s ferroptosis. Then the DNA damage mediated by DHA was accessed again. First, the total LPO accumulation in DHA-treated TAM was reduced with the addition of Fer-1 (Figures 7A,B,K). DDSB caused by DHA was also attenuated by the co-addition of Fer-1 (Figures 7C,D). Moreover, as displayed in Figures 7E–G, the expression of γ-H2A.X and p53 was reduced in the presence of Fer-1 and DHA compared with DHA treatment alone, suggesting that the inhibition of ferroptosis could impair the DHA-induced DNA damage in TAM. Meanwhile, DHA-activated NF-κB was abated by co-treatment with Fer-1, as indicated by the decreased expression of phosphorylated NF-κB (Figures 7H–J and Supplementary Figure S4). Based on these results, the inhibition of ferroptosis in TAM was demonstrated to weaken the DHA-induced DNA damage and activation of NF-κB.
Later, we examined the phenotype of macrophages treated with DHA and Fer-1 in light of revealing the involved crucial mechanism of DHA-induced reprogramming in TAM. Similarly, the key proteins of the M1 phenotype such as CD86, iNOS, and GBP5 were investigated in the presence of DHA and Fer-1. As presented in Figures 8A–F, the biomarkers of the M1 phenotype were down-regulated when co-treated with DHA and Fer-1. Moreover, the inhibition of ferroptosis also attenuated the phagocytosis and antigen presentation functions of DHA-incubated TAM, as evidenced by the decreased endocytic latex beads and MHC-II expression in macrophage (Figures 8G,H). Altogether, evidence has emerged, suggesting a key role of ferroptosis in regulating the phenotypic remodeling in DHA-treated TAM.
Reprogrammed M1-phenotypic macrophages exhibited prominent anti-cancer efficacy

The reprogrammed M1-phenotypic macrophages should have the ability of anti-tumor. To test the anti-tumor efficacy of DHA-treated TAM, Lewis lung cancer cells (LLC) were co-cultured with TAM that received DHA treatment. As expected, the apoptosis rate of LLC increased when co-cultured with TAM treated by DHA (Figures 9A,B). Furthermore, the viability of LLC decreased in the presence of DHA-treated TAM (Figure 9C). At the same time, the expression of Bax and Caspase-3 in LLC was reinforced with the addition of DHA-treated TAM (Figures 9D–F). These data were crucial proof that DHA-mediated reprogramming of TAM boosted anti-tumor immunotherapy.
Discussion and conclusion

In the present work, DHA acted as a ferroptosis inducer to enrich ROS and LPO in TAM. LPO could damage DNA with broken fragments that activate the NF-κB molecule, thereby driving the inflammatory response in TAM, which reprogrammed macrophages into the pro-inflammatory M1 phenotype. The remodeled M1 macrophages could promote apoptosis of lung cancer cells in vitro (Figure 10).

The effect of DHA on inducing ferroptosis has been shown in the work of some scholars and in our previous study (Han et al., 2022). Triggering of ferroptosis requires both enrichment of iron ions and inhibition of the intracellular reducing system (Ye et al., 2020). However, the basal content of iron ions actually varies greatly among different cell types. In our work, the content of iron ions was also shown to be much higher in lung cancer cells than in TAM (Figure 3A). That is why the same concentration of DHA treatment of lung cancer cells caused a significant decrease in their viability (Han et al., 2022) while having a minor effect on TAM viability. In addition, this further leads us to understand the reason why DHA selectively kills tumors with low toxic side effects. Therefore, DHA played a dual role in the fight against lung cancer by directly destroying tumor cells and regulating the immune microenvironment. The fact that the present work has not explored the in vivo efficacy of DHA was a limitation. In general, the efficacy of in vivo studies is the overall result of DHA action on the tumor microenvironment, which cannot be attributed to TAM phenotypic remodeling even if there is prominent efficacy. Therefore, in vitro validation of immune efficacy was conducted. As presented in Figure 9, TAM was first treated with DHA and then co-cultured with lung cancer cells (LLC). The results revealed that DHA-treated TAM could promote apoptosis of LLC. The design of this in vitro study can adequately circumvent the attribution deficiency in the in vivo study.

On the other hand, interestingly, iron ion concentrations differed dramatically in the macrophages but with different phenotypes. Accordingly, the concentration of iron ions is lower in macrophages of the M2 phenotype (Agoro et al., 2018), which is consistent with our work. In contrast, the
majority of macrophages with a pro-inflammatory phenotype (M1 phenotype) had higher iron ion concentrations (Zhou et al., 2018). Nevertheless, prior studies have not elucidated the underlying mechanism of this phenomenon. Instead, our study confirmed that DHA initiated ferroptosis by upregulating TIR1 in combination with the inhibition of GPX4. In turn, the product of ferroptosis, LPO, further activated NF-κB by damaging DNA, thereby contributing to the polarization of macrophages toward the M1 phenotype. In the present study, an intrinsic link between elevated iron ions and macrophage phenotypic remodeling was established thereupon.

How DNA activation of NF-κB was caused by DHA-triggered ferroptosis of TAM was not highlighted in the present study. Nevertheless, the DNA double-strand break (DDSDB) and DNA damage response (DDR) were observed in DHA-treated TAM (Figure 5). Recent studies have demonstrated that broken fragments of DNA released into the cytoplasm can activate the sensor molecule-STING, which is an important signal for anti-tumor immunity (Hopfner and Hornung, 2020; Ma et al., 2020; Reisländer et al., 2020). STING activation can activate its downstream NF-κB molecules, which we mentioned in our study of a photodynamic effect that remodels macrophages to the M1 phenotype (Sun et al., 2020; Yum et al., 2021). But the photodynamic effect is through ROS-mediated DNA damage, while DHA damages DNA by way of LPO generated by ferroptosis. Both are actually inextricably intertwined, but with subtle differences, which could serve as an approaching point for future research.

In conclusion, this work demonstrates that DHA-triggered ferroptosis of TAM results in DNA damage, which could activate downstream NF-κB to remodel TAM to the M1 phenotype (Figure 10), providing a novel strategy for anti-lung cancer immunotherapy. This study offers a novel theoretical basis for the use of traditional Chinese medicine monomers (such as DHA) to regulate the anti-tumor immune response, as well as a new therapeutic approach for TAM phenotype remodeling.

Data availability statement

The original contributions presented in the study are included in the article/Supplementary Material; further inquiries can be directed to the corresponding authors.
Ethics statement

The animal study was reviewed and approved by the Animal Care Committee at the Hubei University of Medicine.

Author contributions

L-GL and X-CP conducted experiments \textit{in vitro} and \textit{in vivo}. T-TY, NH, Q-RL, and H-ZX made data analysis. X-XY, BL, XX, JH, and Z-YY conducted part of the experiments. T-FL, M-FW, T-TY, NH, Q-RL, and H-ZX designed and supervised the work. T-FL wrote the manuscript.

Funding

This work was supported by the Cultivating Project for Young Scholar at Hubei University of Medicine (2020QD/ZR002, 2021QD/ZR015, and 2019QD/ZR02), Innovative Research Program for Graduates of Hubei University of Medicine (YC202027), Advantages Discipline Group (Medicine) Project in Higher Education of Hubei Province (2021-2025 and 2022XXQY2), Precision Medicine Project of Taihe Hospital of Shiyian (2019)JXM007), the National Training Program of Innovation and Entrepreneurship for Undergraduates (202213249001, 202210929004, S202210929007, and S202210929010), the Scientific and Technological Project of Sinopharm DongFeng General Hospital (2022S08), the Foundation of Health Commission of Hubei Province (WJ2021053), and the Science and Technology Research and Development Project of Shiyuan (2021K70).

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors, and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Supplementary material

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fphar.2022.949835/full#supplementary-material

References

Agoro, R., Taleb, M., Queninaux, V. F. J., and Mura, C. (2018). Cell iron status influences macrophage polarization. PLoS One 13 (5), e0196921. doi:10.1371/journal.pone.0196921

Chen, G. Q., Benthani, F. A., Wu, J., Liang, D., Bian, Z. X., Jiang, X., et al. (2020). Artemisinin compounds sensitize cancer cells to ferroptosis by regulating iron homeostasis. Cell Death Differ. 27 (1), 242–254. doi:10.1038/s41418-019-0352-3

Dai, X., Zhang, X., Chen, W., Chen, Y., Zhang, M., Mo, S., et al. (2021). Dihydroartemisinin: a potential natural anticancer drug. Int. J. Mol. Sci. 17 (2), 603–622. doi:10.3390/ijms170305364

Duma, N., Santana-Davila, R., and Molina, J. R. (2019). Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment. Mayo Clin. Proc. 94 (8), 1623–1640. doi:10.1016/j.mayocp.2019.01.013

Han, N., Li, L. G., Peng, X. C., Ma, Q. L., Yang, Z. Y., Wang, X. Y., et al. (2022). Ferroptosis triggered by dihydroartemisinin facilitates chlorin e6 induced photodynamic therapy against lung cancerthrough inhibiting GPX4 and enhancing ROS. Eur. J. Pharmacol. 919, 174797. doi:10.1016/j.ejphar.2022.174797

Hopfner, K. F., and Hornung, V. (2020). Molecular mechanisms and cellular functions of cGAS-STING signalling. Nat. Rev. Mol. Cell Biol. 21 (9), 501–521. doi:10.1038/s41580-020-0244-x

Hou, Y., Liang, H., Rao, E., Zheng, W., Huang, X., Deng, L., et al. (2018). Non-canonical NF-kB antagonizes STING sensor-mediated DNA sensing in radiotherapy. Immunity 49 (3), 490–503. doi:10.1016/j.immuni.2018.07.008

Hwang, I., Kim, J. W., Ylaya, K., Chung, E. J., Kitano, H., Perry, C., et al. (2020). Tumor-associated macrophage, angiogenesis and lymphangiogenesis markers predict prognosis of non-small cell lung cancer patients. J. Transl. Med. 18 (1), 443. doi:10.1186/s12967-020-02618-z

Keating, G. M. (2012). Dihydroartemisinin/piperazine: a review of its use in the treatment of uncomplicated plasmodium falciparum malaria. Drugs 72 (7), 937–961. doi:10.2165/11203910-000000000-00000

Kumar, R., Singh, M., Meena, J., Singhi, P., Thiyagarajan, D., Saneja, A., et al. (2019). Hyaluronic acid – dihydroartemisinin conjugate: synthesis, characterization and in vitro evaluation in lung cancer cells. Int. J. Biol. Macromol. 133, 495–502. doi:10.1016/j.ijbiomac.2019.04.124

Lavin, Y., Kobayashi, S., Leader, A., Amir, E. D., Elefant, N., Bigenwald, C., et al. (2017). Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses. Cell 169 (4), 750–765. doi:10.1016/j.cell.2017.04.014

Li, T. F., Li, K., Wang, C., Liu, X., Wang, Y., Xu, Y. H., et al. (2017). Harnessing the cross-talk between tumor cells and tumor-associated macrophages with a nanodrug for modulation of glioblastoma immune microenvironment. J. Control. Release 268, 128–146. doi:10.1016/j.jconrel.2017.10.024

Li, H., Huang, N., Zhu, W., Wu, J., Yang, X., Teng, W., et al. (2018). Modulation the crosstalk between tumor-associated macrophages and non-small cell lung cancer to inhibit tumor migration and invasion by ginsenoside Rb2. BMC Cancer 18 (1), 579. doi:10.1186/s12885-018-4299-4

Lin, Y. H., Wang, Y. H., Peng, Y. J., Liu, F. C., Lin, G. J., Huang, S. H., et al. (2020). Interleukin 26 skews macrophage polarization towards M1 phenotype by activating cJUN and the NF-kB pathway. Cells 9 (4), 938. doi:10.3390/cells9040938

Liu, J. J., Tang, W., Fu, M., Gong, X. Q., Kong, L., Yao, X. M., et al. (2019). Development of R8 modified epirubicin-dihydroartemisinin liposomes for treatment of non-small cell lung cancer. Artif. Cells Nanom. Biotechnol. 47 (1), 1947–1960. doi:10.1002/1961-0410.2019161532

Lu, C. S., Shiu, A. L., Su, B. H., Hsu, T. S., Wang, C. T., Su, Y. C., et al. (2020). Oct4 promotes M2 macrophage polarization through upregulation of macrophage colony-stimulating factor in lung cancer. J. Hematol. Oncol. 13 (1), 62. doi:10.1186/s13045-020-00887-1

Frontiers in Pharmacology frontiersin.org
Ma, R., Ortiz Serrano, T. P., Davis, J., Prigge, A. D., and Ridge, K. M. (2020). The cGAS-STING pathway: the role of self-DNA sensing in inflammatory lung disease. *FASEB J.* 34 (10), 13156–13170. doi:10.1096/fj.202001667R

Olive, P. L., and Banáth, J. P. (2006). The comet assay: a method to measure DNA damage in individual cells. *Nat. Protoc.* 1 (1), 23–29. doi:10.1038/nprot.2006.5

Osipov, A., Saung, M. T., Zheng, L., and Murphy, A. G. (2019). Small molecule immunomodulation: the tumor microenvironment and overcoming immune escape. *J. Immunother. Cancer* 7 (1), 224. doi:10.1186/s40425-019-0667-0

Parayath, N. N., Parikh, A., and Amju, M. M. (2018). Reorganization of tumor-associated macrophages in a genetically engineered nonsmall cell lung cancer model by intraperitoneal administration of hyaluronic acid-based nanoparticles encapsulating microRNA-125b. *Nano Lett.* 18 (6), 3571–3579. doi:10.1021/acs.nanolett.8b00689

Reislander, T., Groelly, F. J., and Tarsounas, M. (2020). DNA damage and cancer immunotherapy: a STING in the tale. *Mol. Cell* 80 (1), 21–28. doi:10.1016/j.molcel.2020.07.026

Sarode, P., Zheng, X., Giotopoulou, G. A., Weigert, A., Kuenne, C., Günther, S., et al. (2020). Reprogramming of tumor-associated macrophages by targeting β-catenin/FOSL2/ARID5A signaling: A potential treatment of lung cancer. *Sci. Adv.* 6 (23), eaaz6105. doi:10.1126/sciadv.aaz6105

Siegel, R. L., Miller, K. D., Fuchs, H. E., and Jemal, A. (2022). Cancer statistics, 2022. *CA. Cancer J. Clin.* 72 (1), 7–33. doi:10.3322/caac.21708

Singhal, S., Stadnick, J., Annunziata, M. J., Rao, A. S., Bhojnagarwala, P. S., O’Brien, S., et al. (2019). Human tumor-associated monocyes/macrophages and their regulation of T cell responses in early-stage lung cancer. *Sci. Transl. Med.* 11 (479), eaatt1500. doi:10.1126/scitranslmed.aat1500

Sun, X., Xie, Z., Hu, B., Zhang, B., Ma, Y., Pan, X., et al. (2020). The Nrf2 activator RTA-408 attenuates osteoclastogenesis by inhibiting STING dependent NF-κB signaling. *Redox Biol.* 28, 101309. doi:10.1016/j.redox.2019.101309

Tu, Y. (2016). Artemisinin-A gift from traditional Chinese medicine to the world (nobel lecture). *Angew. Chem. Int. Ed. Engl.* 55 (35), 10210–10226. doi:10.1002/anie.201601987

Wan, X., Zhong, H., Pan, W., Li, Y., Chen, Y., Li, N., et al. (2019). Programmed release of dihydroartemisinin for synergistic cancer therapy using a CaCO3 mineralized metal-organic framework. *Angew. Chem. Int. Ed. Engl.* 58 (40), 14134–14139. doi:10.1002/anie.201903788

Wei, C., Yang, C., Wang, S., Shi, D., Zhang, C., Lin, X., et al. (2019). Crosstalk between cancer cells and tumor associated macrophages is required for mesenchymal circulating tumor cell-mediated colorectal cancer metastasis. *Mod. Cancer 18 (1), 64. doi:10.1186/s12943-019-0976-4

Xu, H. Z., Li, T. F., Wang, C., Ma, Y., Liu, Y., Zheng, M. Y., et al. (2021). Synergy of nanodiamond-doxorubicin conjugates and PD-L1 blockade effectively turns tumor-associated macrophages against tumor cells. *J. Nanobiotechnol.* 19 (1), 268. doi:10.1186/s12951-021-01017-w

Yang, D., Liu, Y., Bai, C., Wang, X., and Powell, C. A. (2020). Epidemiology of lung cancer and lung cancer screening programs in China and the United States. *Cancer Lett.* 466, 82–87. doi:10.1016/j.canlet.2019.10.009

Ye, Z., Liu, W., Zhuo, Q., Hu, Q., Liu, M., Sun, Q., et al. (2020). Ferroptosis: Final destination for cancer? *Cell Prolif.* 53 (3), e12761. doi:10.1111/cpr.12761

Yu, R., Wang, H., Deng, C., Wang, X., Yao, L., Niu, W., et al. (2020). Dihydroartemisinin initiates ferroptosis in glioblastoma through GPX4 inhibition. *Biosci. Rep.* 40 (6), BSR20193314. doi:10.1042/BSR20193314

Yu, T. T., Sang, X. Y., Han, N., Peng, X. C., Li, Q. R., Xu, X., et al. (2021). Macrophages mediated delivery of chlorin e6 and treatment of lung cancer by photodynamic reprogramming. *Int. Immunopharmacol.* 100, 108164. doi:10.1016/j.intimp.2021.108164

Yu, T. T., Peng, X. C., Wang, M. F., Han, N., Xu, H. Z., Li, Q. R., et al. (2022). Chlorin e6-Induced Photodynamic Effect Polarizes the Macrophage Into an M1 Phenotype Through Oxidative DNA Damage and Activation of STING. *Front. Pharmacol.* 13, 873774. doi:10.3389/fphar.2022.873774

Yum, S., Li, M., Fang, Y., and Chen, Z. J. (2021). TBK1 recruitment to STING activates both IRF3 and NF-κB that mediate immune defense against tumors and viral infections. *Proc. Natl. Acad. Sci. U. S. A.* 118 (14), e2100225118. doi:10.1073/pnas.2100225118

Zhou, Y., Que, K. T., Zhang, Z., Yi, Z. J., Zhao, P. X., You, Y., et al. (2018). Iron overloaded polarizes macrophage to proinflammation phenotype through ROS/acetyl-p53 pathway. *Cancer Med.* 7 (8), 4012–4022. doi:10.1002/cam4.1670